*Submit your email address to receive conference udpates

BioTrinity 2008 Oxford - Business Growth BioPartnering

April 15-16, 2008 - Quadrangle at Kassam, Oxford, UK

500+ one-to-one partnering meetings
2000 meeting requests
400+ delegates
270 companies
12 countries represented

'I found the feedback from presenting at the OBN meeting truly excellent. I not only had a lot of questions after the presentation but it generated press interest and many follow up meetings in the following days. This is testament to the quality of the attendees at the meeting'
David Phillips, SVP, Sales and Marketing, BioFocus DPI (part of Galapagos), 23 April 2008

BioTrinity 2009 will take place April 2-3, 2009

Building value in a bioscience company isn’t easy. Raising your company’s profile and establishing high-quality partners in finance, licensing and business development takes time and effort. But now there’s a proven fast-track approach: BioTrinity 2008 Oxford, the largest biotech partnering conference in the South-East of England.

BioTrinity 2008 has confirmed delegates from GSK, Teva, Takeda, AstraZeneca, Merck, Genzyme, Bristol-Myers Squib, and Shire, and VCs and investment firms including Abingworth, SR One, Sofinnova, Orion Healthcare Equity Partners, Oxford Capital Partners, Sunstone Capital, MP Healthcare Venture Management, Innovator Capital, Wellcome, Xiota, Beer and Partners, Catalyst Venture Partners, Noble & Co, Cannacord Capital, Nomura Code and NYSE Euronext giving you the access you need. See which other companies are participating.

Partnering is live - over 1900 meeting requests already in the system! Register now to partner.

As the annual showcase event for the regional bioscience super-cluster, BioTrinity 2008 Oxford brings together decision-makers from biotech and pharma together with expert professional advisers and VC finance representatives. And with its proven “gold standard” online industry partnering service, delegates can pre-book up to 36 one-to-one meetings over two days in private rooms.

There’s no doubt that the BioTrinity format works. Last year over 500 partnering meetings brought together more than 400 delegates from nearly 300 companies to discuss over 185 licensing opportunities. And this year the event promises to be even bigger: for example, companies already booked to present at BioTrinity 2008 Oxford have 33 compounds in pre-clinical development and 25 in clinical development, excluding big pharma participants. Add to that access to networking receptions, international panel discussions, company showcases and essential workshops all promises to make this the “must attend” event of the year. Can you afford not to attend?

Take a look at the rapidly growing list of over 260 companies already confirmed as participating in BioTrinity 2008 - Oxford, which covers about 400 delegates so far

Testimonials (read more testimonials):
"...I would like to congratulate you on an excellent meeting."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event … I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me."
Dr Charles Potter, CEO, Glide Pharma

"...the conference was a great success. There was a high calibre of participants and the event has raised the profile the Oxford and Thames Valley biotech cluster. This will create a rising tide for us all."
David Mott, Investment Director, Oxford Capital Partners

BioTrinity is the largest biotech & healthcare partnering conference in the Oxford & South East biotech region, and is unique in showcasing this super-cluster's biotech companies, which lead the UK in attracting investment.

To secure your participation in BioTrinity 2008 - Oxford , register online now: